TLDR:
- Capricor (CAPR) prices $150M offering to boost DMD treatment development and manufacturing.
- Capricor (CAPR) launches $150M offering for Deramiocel and rare disease therapies.
- Capricor (NASDAQ: CAPR) to raise $150M for DMD treatment via public offering.
- Capricor (CAPR) prices public offering at $25 per share, raising $150M for DMD research.
- Capricor Therapeutics (CAPR) targets $150M offering to accelerate DMD therapy development.
Capricor Therapeutics (NASDAQ: CAPR) has announced the pricing of its underwritten public offering of common stock. The company will sell 6,000,000 shares at a public offering price of $25.00 per share. This offering is expected to generate gross proceeds of $150 million before fees, with the option for underwriters to purchase up to an additional 900,000 shares.
Proceeds to Fund Product Development and Corporate Expansion
The net proceeds from the offering are intended for continued development of Capricor’s product candidates. These include their lead product, Deramiocel, a cell therapy in late-stage clinical development for Duchenne muscular dystrophy (DMD). The company plans to use the funds for manufacturing, working capital, and general corporate purposes.
Capricor is advancing its research with a strong focus on DMD treatments. Deramiocel has shown promising preclinical and clinical data, demonstrating its ability to preserve cardiac and skeletal muscle function. With the funding, Capricor aims to accelerate the product’s development and bring it closer to market approval.
The company also plans to use part of the offering proceeds to support its proprietary StealthX™ platform. This platform is being developed for targeted delivery of therapeutics, including oligonucleotides and proteins. Capricor intends to leverage the platform for a range of diseases, expanding its pipeline beyond DMD.
Underwriters and Expected Closing Details
The public offering is being led by Piper Sandler and Oppenheimer & Co., with H.C. Wainwright & Co. acting as the co-manager. The offering is expected to close on or about December 8, 2025, subject to customary closing conditions. The underwriters have been granted a 30-day option to purchase up to 900,000 additional shares at the offering price, minus discounts and commissions.
Capricor filed the offering under a Form S-3 shelf registration statement, which was declared effective in September 2025. The offering will be made only by means of a prospectus and related prospectus supplement, which will be available from the underwriters. The public offering marks a critical step in securing funding for Capricor’s ongoing and future projects in rare disease therapeutics.
Capricor continues to make strides in its mission to develop transformative therapies for rare diseases. The company’s strategic approach, including its partnership for commercialization in the U.S. and Japan, positions it for sustained growth in the biotechnology sector. With this offering, Capricor is poised to enhance its financial stability and push its innovative treatments forward.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
